Waldenstrom Macroglobulinemia
Conditions
Keywords
Advanced Waldenström's macroglobulinemia, Bortezomib, Dexamethasone, Safety, Efficacy
Brief summary
This trial is designed to evaluate the efficacy and toxicity of Bortezomib , an inhibitor of proteasome used in multiple myeloma, in patients with advanced Waldenström's Macroglobulinemia disease.
Detailed description
Open, prospective, multicenter, non controlled phase IIA trial Primary objectives Evaluation of the efficacy and safety of Velcade in monotherapy for patients with advanced stage Waldenström Macroglobulinemia. Secondary objectives Evaluation of the activity of the association of High Dose Dexamethasone (HD DXM) with Velcade for patients resistant to Velcade Alone For all patients * Overall survival * Safety * Quality of life * Duration of response sample size: With type I error alpha of 5% and type II error beta of 20% and a two-sided test, the number of patients needed in this study is 34 Number of centers: 28 Centers participating to the French cooperative group CLL/WM
Interventions
DRUGBORTEZOMIB
* Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push). * For responding patients : up to 6 cycles * For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
● Established diagnosis of Waldenström macroglobulinemia (the 2nd Workshop on Waldenstrom's macroglobulinemia) Patient must have had 1 (or 2) lines of chemotherapy containing alkylating agent and/or Fludarabine :and /or monoclonal antibody and must have : * Life expectancy \> 3 months * Age \> 18 years * ECOG performance status 0-1-2 * ANC \> 1 x 109/L * Creatinine clearance, calculated according to the formula of cockcroft and Gault \> 40 ml/min * Total bilirubin \< 2x ULN * ASAT, ALAT \< 2x ULN * A negative serum pregnancy test one week prior to treatment must be available both for pre-menopausal women and for women who are \< 2 years after the onset of menopause * Adequate contraceptive methods for males and pre-menopausal females for 6 months after treatment discontinuation. * Written informed consent * Platelets\> 100X 109
Exclusion criteria
* Active secondary malignancy or chemotherapy/radiotherapy for any neoplastic disease other than Waldenström macroglobulinemia prior to the study * Medical condition requiring the long-term (estimated to be more than one month) use of oral corticosteroids * Patients with active bacterial, viral or fungal infection * Known infection with HIV, Hepatitis B (except post vaccinal profile) or C * Treatment with any, other investigational agent or participating in another trial within 30 days prior to entering this study * Lactation/pregnancy * Concurrent severe diseases which exclude the administration of therapy heart insufficiency NYHA grade III/IV, LEVF \< 50% and or RF \< 30%, myocardial infarction within the past 6 months prior to study * Severe pulmonary or heart problems (acute diffuse pulmonary and pericardial disease) * Severe chronic obstructive lung disease with hypoxemia * Severe diabetes mellitus * Hypertension difficult to control * Impaired renal function with creatinine clearance \< 40 ml/min according to the formula of Cockcroft and Gault * Cerebral dysfunction * Richter's syndrome * Neuropathy\> grade 1 * Positive Beta HCG * Severe Hepato cellular alteration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete and partial remission, defined by the 2nd Workshop on Waldenstrom's macroglobulinemia | 3 months and 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Duration of the response | during the study |
| Overall survival | during the study |
| Quality of life | months 0, 3, 12, 24 |
Countries
France
Outcome results
None listed